Trials / Completed
CompletedNCT02784002
A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)
A Phase II, Randomized, Open-Label, Active-Controlled Clinical Study to Investigate the Safety and Efficacy of SMT19969 (200mg BID) for 10 Days Compared With Fidaxomicin (200 mg BID) for 10 Days for the Treatment of Clostridium Difficile Infection (CDI)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Summit Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to evaluate the safety and effectiveness of Ridinilazole (SMT19969) in treating C. difficile Infection (CDI).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ridinilazole | |
| DRUG | Fidaxomicin |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2016-08-01
- Completion
- 2016-08-01
- First posted
- 2016-05-26
- Last updated
- 2017-10-12
Locations
16 sites across 3 countries: United States, Czechia, United Kingdom
Source: ClinicalTrials.gov record NCT02784002. Inclusion in this directory is not an endorsement.